Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous golimumab in pediatric polyarticular-course juvenile idiopathic arthritis despite methotrexate
NL-OMON36723Phase 3Active, not recruiting
- Sponsor
- Janssen Biotech
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Golimumab continuation with Placebo withdrawal (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2011; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON36723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36723.